Attendee search 

senescence company

PCS provides new product engineering and design services for medical device and Medtech companies. We have served enterprise and entrepreneurs for over two decades and our QMS is ISO13485:2016 certified.

Charnwood Molecular is an award-winning, UK-based CRO, which has been providing expert synthetic chemistry support for over 20 years. At Charnwood Molecular, we work with clients of all shapes, sizes and global standing. These range across a variety of sectors, from virtual start-ups to established global agrochemical, materials chemistry, diagnostics, biotechnology and pharmaceutical companies. All of our clients benefit from our proactive and open approach, geared towards rapidly advancing projects towards important key decision points and beyond.

We are a cross-border private equity fund dedicated to actively pursuing primarily late stage U.S healthcare companies that will benefit from penetrating the vast Asian healthcare market. We identify the well-managed western companies with advanced technology or systems to disrupt the global healthcare market, especially the ones with great market potential in Asia.

Alignment Ventures is a seed stage life science venture fund with heavy operational emphasis. We typically spin companies out of University technology and serve as the Founding CEO until we can hit sufficient milestones to raise a Series A financing. In this fashion, Partner, Michael Tippie was CEO of TomegaVax until 2016 when that company was acquired by Vir Biotechnology. Vir is now a $4 BB+ public company.

Leading global PE

mRNA Company focusing on HBV, diabetes, seasonal flu, and nash

A publicly-traded bioceutical research, development and marketing firm with over 40 products backed by a combined $68 million in research and development and clinical studies. TRICCAR solutions support health challenges affecting over 6 billion people worldwide, beginning with four products to be introduced in 2021:

AVL™ - Antiviral immunity support
Global audience size: 6.2+ billion

CAL™ - Calcium deficiency
Global audience size: 6+ billion

OFF™ - Weight and obesity management
Global audience size: 1+ billion

CLM™ - Menopausal support
Global audience size: 500+ million

Having met 85%> effectiveness in placebo-based, double-blind studies, TRICCAR’s products are ready for market introduction as over-the-counter, direct-to-consumer bioceutical products. An additional 8 products will undergo Food and Drug Administration (FDA) approval. Our initial four products are targeted towards women, ages 25-65, yet appeal to all demographics and genders.

We sell via our patented and patent-pending direct-to-consumer marketing technologies that have historically generated $18 in revenue for every $1 spent compared to industry averages of $2 for every $1 spent. We add to these efforts with retail (ex. Walgreens, CVS, COSTCO, etc.) and online marketplaces (ex. Walmart.com, Amazon.com), and a 130,000 physician/chiropractor network.

Our Series B Convertible Preferred PIPE offering minimizes investor risk while providing significant potential upside. TRICCAR anticipates 3-year total revenue to exceed $163.2 million. Based on comparable price/sales valuations, this could indicate a market cap of approximately $403.5 million at time of conversion.